Impact Biomedical Inc (IBO)

$0.44 +0.01 (2.30%)
Market Cap 47.55M
Revenue (ttm) 30,000.00
Net Income (ttm) -11.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39,466.67%
Debt to Equity Ratio 0.00
Volume 26,124
Avg Vol 61,926
Day's Range N/A - N/A
Shares Out 107.82M
Stochastic %K 31%
Beta 2.74
Analysts Strong Buy
Price Target N/A

Company Profile

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a uni...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 415 6576
Address:
1400 Broadfield Blvd., Suite 130, Houston, United States
ParkdaleTrader
ParkdaleTrader Jul. 23 at 7:34 PM
$IBO
0 · Reply
Render80
Render80 Jul. 22 at 6:46 PM
$IBO This is the topic of the documentary....
0 · Reply
johannn
johannn Jul. 22 at 6:06 PM
$IBO $DSS $AEI $HWH That is finally a great idea: making a documentary about how the so-called SEC-monitored American stock exchange is used by scammers. These scammers set up so-called companies that are nothing more than a mailing address with no past or future income. These castles in the air are assigned exaggerated valuations by so-called independent valuation experts. And the SEC lets it all happen.🕵️🕵️🥷🥷
1 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 20 at 3:23 PM
$IBO this thing needs some news, been dead too long
1 · Reply
johannn
johannn Jul. 20 at 12:11 PM
$DSS $IBO $AEI $HWH "Our lawyers" have stolen millions, but no one is locking them up; the SEC is asleep.
0 · Reply
stevero
stevero Jul. 17 at 4:53 PM
$IBO Re. ProPhase Labs.. Ted Karkus Pumped Collections were aggressively being Collected by a group of experienced attorney's at Crown Collections. That most likely was 99.9% Bull Shit. The address and ambiguity of the firm listed hints at the real story. I asked AI the following question: What business is the master lease holder for Suite 1000 at 4801 E. Independence Blvd. Charlotte, No Carolina 28212 Short answer — Public records list Carolina Gold Executive Suites, Incorporated as the business registered at Suite 1000 and Master lease holder — Suite 1000 Primary public‑record listing: Carolina Gold Executive Suites, Incorporated is shown in No. Carolina business records with its principal office and registered agent at 4801 E. Independence Blvd., Suite 1000, Charlotte, NC 28212, and its business description is real estate management, operating a real‑estate/office‑suite business at that address; however several other entities also use Suite 1000 as their principal mailing address.
1 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 16 at 7:54 PM
$IBO AH pump or fakeout?
0 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 16 at 7:24 PM
$IBO it’s looking pretty dead
0 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 13 at 4:32 PM
$IBO getting some movement, neefs to beeak .50 and .56
0 · Reply
johannn
johannn Jul. 9 at 4:02 PM
$IBO $DSS $AEI $HWH
0 · Reply
Latest News on IBO
Impact BioMedical Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

Impact BioMedical Quarterly report: Q1 2026

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

Apr 3, 2026, 1:52 PM EDT - 3 months ago

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

Impact BioMedical Annual report: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 4 months ago

Impact BioMedical Annual report: Q4 2025

Why Is Impact BioMedical Stock (IBO) Up Today?

2026-03-05T13:17:27.000Z - 5 months ago

Why Is Impact BioMedical Stock (IBO) Up Today?

DSS

Impact BioMedical Quarterly report: Q3 2025

Nov 7, 2025, 4:00 PM EST - 9 months ago

Impact BioMedical Quarterly report: Q3 2025

Impact BioMedical Proxy statement: Proxy Filing

Sep 22, 2025, 8:00 AM EDT - 10 months ago

Impact BioMedical Proxy statement: Proxy Filing

Impact BioMedical announces 3F U.S. patent issue

2025-08-18T12:40:35.000Z - 1 year ago

Impact BioMedical announces 3F U.S. patent issue

Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

Impact BioMedical Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Impact BioMedical Quarterly report: Q2 2025

Why Is Impact BioMedical Stock (IBO) Up 200% Today?

2025-06-24T01:29:00.000Z - 1 year ago

Why Is Impact BioMedical Stock (IBO) Up 200% Today?

Impact BioMedical, Dr Ashleys enter strategic merger agreement

2025-06-23T17:04:06.000Z - 1 year ago

Impact BioMedical, Dr Ashleys enter strategic merger agreement

Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

Jun 23, 2025, 7:52 AM EDT - 1 year ago

Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

Impact BioMedical Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Impact BioMedical Quarterly report: Q1 2025

Biotech Alert: Searches spiking for these stocks today

2025-05-05T16:11:45.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ADIL ADPT ARDX BIVI CYTK ELAB MAIA

Impact BioMedical Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Impact BioMedical Annual report: Q4 2024

Impact Biomedical Inc. Announcement Stock Activity/Pricing

Mar 21, 2025, 2:38 PM EDT - 1 year ago

Impact Biomedical Inc. Announcement Stock Activity/Pricing

Impact BioMedical announces acquisition of Celios in $1.15M equity transaction

2025-02-26T13:46:39.000Z - 1 year ago

Impact BioMedical announces acquisition of Celios in $1.15M equity transaction

DSS announces sale of Celios to Impact BioMedical

2025-02-26T13:41:33.000Z - 1 year ago

DSS announces sale of Celios to Impact BioMedical

DSS

Impact BioMedical Inc. to Present at The Microcap Conference

Jan 23, 2025, 4:30 PM EST - 1 year ago

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical CEO says ‘well-positioned’ to drive long-term value

2024-11-19T13:10:19.000Z - 1 year ago

Impact BioMedical CEO says ‘well-positioned’ to drive long-term value

Impact BioMedical Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Impact BioMedical Quarterly report: Q3 2024

Impact BioMedical issued Canadian patent for Linebacker technology

2024-10-15T10:05:14.000Z - 1 year ago

Impact BioMedical issued Canadian patent for Linebacker technology

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

Oct 15, 2024, 6:00 AM EDT - 1 year ago

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

Impact BioMedical announces completion of IPO

2024-10-07T12:42:48.000Z - 1 year ago

Impact BioMedical announces completion of IPO

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

Impact BioMedical announces 3F US patent issue

2024-09-26T12:37:46.000Z - 1 year ago

Impact BioMedical announces 3F US patent issue

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

Impact BioMedical appoints Frank Heuszel as CEO, Mark Suseck as COO

2024-09-24T09:05:48.000Z - 1 year ago

Impact BioMedical appoints Frank Heuszel as CEO, Mark Suseck as COO

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Sep 17, 2024, 11:29 AM EDT - 2 years ago

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Impact BioMedical Inc. Announces Pricing of Initial Public Offering

Sep 16, 2024, 10:24 AM EDT - 2 years ago

Impact BioMedical Inc. Announces Pricing of Initial Public Offering

ParkdaleTrader
ParkdaleTrader Jul. 23 at 7:34 PM
$IBO
0 · Reply
Render80
Render80 Jul. 22 at 6:46 PM
$IBO This is the topic of the documentary....
0 · Reply
johannn
johannn Jul. 22 at 6:06 PM
$IBO $DSS $AEI $HWH That is finally a great idea: making a documentary about how the so-called SEC-monitored American stock exchange is used by scammers. These scammers set up so-called companies that are nothing more than a mailing address with no past or future income. These castles in the air are assigned exaggerated valuations by so-called independent valuation experts. And the SEC lets it all happen.🕵️🕵️🥷🥷
1 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 20 at 3:23 PM
$IBO this thing needs some news, been dead too long
1 · Reply
johannn
johannn Jul. 20 at 12:11 PM
$DSS $IBO $AEI $HWH "Our lawyers" have stolen millions, but no one is locking them up; the SEC is asleep.
0 · Reply
stevero
stevero Jul. 17 at 4:53 PM
$IBO Re. ProPhase Labs.. Ted Karkus Pumped Collections were aggressively being Collected by a group of experienced attorney's at Crown Collections. That most likely was 99.9% Bull Shit. The address and ambiguity of the firm listed hints at the real story. I asked AI the following question: What business is the master lease holder for Suite 1000 at 4801 E. Independence Blvd. Charlotte, No Carolina 28212 Short answer — Public records list Carolina Gold Executive Suites, Incorporated as the business registered at Suite 1000 and Master lease holder — Suite 1000 Primary public‑record listing: Carolina Gold Executive Suites, Incorporated is shown in No. Carolina business records with its principal office and registered agent at 4801 E. Independence Blvd., Suite 1000, Charlotte, NC 28212, and its business description is real estate management, operating a real‑estate/office‑suite business at that address; however several other entities also use Suite 1000 as their principal mailing address.
1 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 16 at 7:54 PM
$IBO AH pump or fakeout?
0 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 16 at 7:24 PM
$IBO it’s looking pretty dead
0 · Reply
ParkdaleTrader
ParkdaleTrader Jul. 13 at 4:32 PM
$IBO getting some movement, neefs to beeak .50 and .56
0 · Reply
johannn
johannn Jul. 9 at 4:02 PM
$IBO $DSS $AEI $HWH
0 · Reply
Render80
Render80 Jul. 9 at 12:46 PM
$IBO We have taken a deep dive into all companies associated with Chan's network and have mapped the following:
0 · Reply
Render80
Render80 Jul. 6 at 1:13 PM
$IBO Curious to see if IBO files yet another extension with the SEC regarding this deal. Also I am puzzled how they have not disclosed in filings that the Rosen Law firm has launched an investigation and that I have also alerted IBO and Dr. Ashleys that I intend to pursue the return of the Equivir and Linebacker technologies.
0 · Reply
Spc_baller
Spc_baller Jul. 4 at 1:17 AM
$IBO great news should be inbound, hanging tight
0 · Reply
johannn
johannn Jul. 1 at 6:40 PM
$IBO $DSS $AEI $HWH Well, well, it’s already been over a year and still no strategic merger https://www.impactbiomedinc.com/dr-ashleys-limited-and-impact-biomedical-inc-announce-strategic-merger/ And on April 03, 2026 at 13:52 ET another worthless press release came from these scammers, in which we are lied to about a new date again, namely .... Separately, Impact Biomedical continues with strategic plans to merge with Dr. Ashley’s Ltd. (here), projected to be completed by July 1, 2026. https://www.globenewswire.com/news-release/2026/04/03/3268111/0/en/impact-biomedical-inc-reports-going-concern-audit-opinion-in-2025-10-k-filing-while-continuing-strategic-merger-plans.html It appears that the merger involving the two fraudulent companies IBO and Dr Ashley, which is now called Zoar Inc. after a name change, will not go ahead; that was, of course, to be expected.🕵️🕵️🥷🥷
0 · Reply
Render80
Render80 Jul. 1 at 2:45 PM
$IBO This deal is going no where... the technology is obsolete. Its just an attorney sitting behind a desk playing stock games. No real work being done here... I know, my firm developed the technology for this group in exchange for a royalty. They canceled the agreement right before they IPO'd. Starting portraying themselves as the developer of the tech. The technology is now very obsolete and they have now learned the hard way how Karma works in biotech.
0 · Reply
BowhuntinLineman
BowhuntinLineman Jul. 1 at 12:57 PM
$IBO today the day ?
1 · Reply
BowhuntinLineman
BowhuntinLineman Jun. 30 at 8:48 PM
$IBO what will tomorrow look like ? Green fields or bloody water?
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jun. 28 at 6:25 PM
Small-Caps with Catalysts this week: 👇👇 ( $PHIO, $SXTP, $PSEC, $IBO, $LHAI, etc...) #NASDAQ #NYSE
0 · Reply
johannn
johannn Jun. 25 at 8:33 PM
$DSS $IBO $AEI $HWH As was to be expected, since the real market is not interested in these scam stocks, they just continue shuffling junk around among themselves to let the dilution continue. https://www.sec.gov/ix?doc=/Archives/edgar/data/0000771999/000149315226030115/form8-k.htm
0 · Reply
AlexeiMoro
AlexeiMoro Jun. 18 at 1:05 AM
$IBO Active patent development pipeline:: -Company has secured and expanded U.S. and international patents Recent filings include infectious disease and functional compound protection....
0 · Reply
Render80
Render80 Jun. 9 at 5:47 PM
$IBO This is what AI is saying: The Rosen Law Firm is currently gathering data from affected shareholders to prepare a formal securities class action lawsuit. The goal of the prospective lawsuit is to recover financial losses suffered by individuals who purchased Impact BioMedical securities under the influence of the allegedly misleading public statements.
0 · Reply
Render80
Render80 Jun. 9 at 5:00 PM
$IBO Impact BioMedical, Inc. (ticker: IBO) is facing shareholder class action investigations regarding whether its board and executives violated federal securities laws or breached their fiduciary duties during corporate mergers and asset transactions. Several national investor rights firms, such as the Rosen Law Firm and Halper Sadeh LLC, are investigating these claims.These legal developments primarily impact shareholders and investors in Impact BioMedical in the following ways:Corporate Board Accountability: Investigations center on whether Impact BioMedical’s board of directors engaged in unfair deal processes or failed to maximize shareholder value during mergers and acquisitions.Shareholder Rights & Recoveries: Institutional and retail investors who hold or purchased IBO stock are being evaluated to see if they are entitled to recover financial losses or challenge the terms of recent transactions.
0 · Reply